TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06781866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: A relaxation type of massage will be used as the main massage intervention in this study. This technique is designed to promote deep relaxation, reduce stress, and enhance overall well-being. It is characterized by the use of five primary techniques performed on the full body, including the palms and feet. Specifically, these techniques consist of effleurage (long, gliding strokes), petrissage (kneading and squeezing), tapotement (rhythmic tapping), friction (deep, circular rubbing), and vibration or shaking movements (Table 1). In addition to these, the technique also incorporates rhythmic movements and deep light pressure to enhance relaxation and alleviate tension. It is designed to promote relaxation, increase blood circulation, relieve muscle tension, improve flexibility and promote relaxation and reduce pain. The total duration of the Relaxation massage is 45 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: The Sham massage (PLA) will be used as a control session, without applying the deeper techniques that characterize the Relaxation massage in order to eliminate the influence of the human touch sensation on the participant's skin. This massage consisted only of superficial oil application movements over the entire body, without any added pressure or deep muscle manipulation. Oil was used to facilitate smooth gliding, mimicking the sensation of a full massage, but without the intensity or techniques aimed at muscle tissue relaxation. The total duration of the sham massage is 45 minutes.
Study: NCT06772727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: After preoxygenation with 100% oxygen for 3 minutes, the study drug (lidocaine) will be administered. Patients will receive 1 mg/kg lidocaine of 10 mg/mL lidocaine solution (prepared by diluting 5 mL of lidocaine 20% in saline to a total volume of 10 mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: After preoxygenation with 100% oxygen for 3 minutes, the study drug (fentanyl) will be administered. Patients will receive 1 mcg/kg fentanyl of 10 mcg/mL fentanyl solution (prepared by diluting 100 mcg fentanyl in saline to a total volume of 10 mL).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: After administration of the study drug, all patients will receive 2 mg/kg propofol intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: After administration of the study drug, all patients will receive 2 mg/kg propofol intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinyl choline
Description: After loss of consciousness, 1 mg/kg succinyl choline will be administered over 5 seconds, and tracheal intubation will be done through direct laryngoscopy after 60 seconds.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinyl choline
Description: After loss of consciousness, 1 mg/kg succinyl choline will be administered over 5 seconds, and tracheal intubation will be done through direct laryngoscopy after 60 seconds.
Study: NCT06774612

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ChatGPT-4o
Description: OpenAI's ChatGPT-4o large language model with chat interface.
Study: NCT06302140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Nanatinostat
Description: A single oral dose administered on Day 1 in a fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanatinostat (free base) tablets in combination with Valganciclovir
Description: Treatment A: a single, oral dose of nanatinostat (free base) tablets (20 mg) in combination with valganciclovir (900 mg) under fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanatinostat mesylate tablets in combination with Valganciclovir
Description: Treatment B: a single, oral dose of nanatinostat mesylate tablets (20 mg) in combination with valganciclovir (900 mg) under fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single-agent Nanatinostat (free base) tablets
Description: 40 mg once daily under fed conditions until disease progression or unacceptable toxicity, whichever occurs first.
Study: NCT05162261

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tixel C
Description: Tixel C by Novoxel®, Israel is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling tissue coagulation combined with micro ablation with low thermal damage to the surrounding tissue.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LipiFlow
Description: Thermal pulsation (LipiFlow) consists of the localized application of heat and therapeutic pressure on the four eyelids (upper and lower) with the aim of improving drainage of the Meibomian glands.
Study: NCT05554029

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Coronaphobia
Description: Coronophobia will be assessed with COVID-19-phobia scale.
Study: NCT05649670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Stroke Unit deployment
Description: Deployment of an MSU + conventional ambulance, allowing prehospital CT-scan imaging with intracranial CT angiography. This will allow prehospital intravenous thrombolysis and optimal triage (i.e. accurate identification of patients with large vessel occlusion, who are eligible for mechanical thrombectomy).
Study: NCT06377293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysis-specific therapeutic diet
Description: A healthy diet for dialysis patients
Study: NCT05982106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ05105 Tablets
Description: TQ05105 tablet is a novel JAK2 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ05105 Tablets
Description: TQ05105 tablet is a novel JAK2 inhibitor.
Study: NCT06265090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic exercises
Description: Protocol of hemibridge with ball and balloon exercise Participants were given exercise called as hemibridge with ball and balloon exercise for 3 sessions over 3 days/week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic exercises
Description: Protocol of hemibridge with ball and balloon exercise Participants were given exercise called as hemibridge with ball and balloon exercise for 3 sessions over 3 days/week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: The second group received hemibridge with ball and balloon exercise in combination to core stability exercises.~Protocol of hemibridge with ball and balloon exercise The hemibridge with ball as well as balloon exercise was provided to the participants over the course of three sessions per week.~Instructions~1. supine-lying position, feet up against a wall, and bend your knees as well as hips to a 90° angle.~2. Insert a ball measuring between four and six inches in diameter in the space between your knees.~3. Put your left hand upon a balloon and your right arm above your head.~4. Tilt your pelvis to make sure your tailbone is just slightly elevated off the ground while you inhale with your nose and exhale using your mouth. Keep your low back as flat as possible on the mat. Dig your heels into the wall instead of pushing your feet flat.~5. drop your left knee till it is below the level of your right, without moving your feet. the activation of your left inner thigh muscle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Description: The second group received hemibridge with ball and balloon exercise in combination to core stability exercises.~Protocol of hemibridge with ball and balloon exercise The hemibridge with ball as well as balloon exercise was provided to the participants over the course of three sessions per week.~Instructions~1. supine-lying position, feet up against a wall, and bend your knees as well as hips to a 90° angle.~2. Insert a ball measuring between four and six inches in diameter in the space between your knees.~3. Put your left hand upon a balloon and your right arm above your head.~4. Tilt your pelvis to make sure your tailbone is just slightly elevated off the ground while you inhale with your nose and exhale using your mouth. Keep your low back as flat as possible on the mat. Dig your heels into the wall instead of pushing your feet flat.~5. drop your left knee till it is below the level of your right, without moving your feet. the activation of your left inner thigh muscle.
Study: NCT05436561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBF-RIC
Description: Reduced intensity conditioning regimen with fludarabine, busulfan and melphalan
Study: NCT05594147

Intervention type: DRUG
Intervention: Non-TKIs
Description: Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.

Intervention type: DRUG
Intervention: Other TKIs
Description: Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.

Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY73- 4506)
Description: Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
Study: NCT06107647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COVIDIEN WarmTouch
Description: COVIDIEN WarmTouch will be used as an active air blowing heater. Patients will be warmed starting from the beginning of anesthesia.~The INDITHERM Medical Alpha, which is a resistive heater, will be applied to patients starting at the beginning of anesthesia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COVIDIEN WarmTouch
Description: COVIDIEN WarmTouch will be used as an active air blowing heater. Patients will be warmed starting from the beginning of anesthesia.~The INDITHERM Medical Alpha, which is a resistive heater, will be applied to patients starting at the beginning of anesthesia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COVIDIEN WarmTouch
Description: COVIDIEN WarmTouch will be used as an active air blowing heater. Patients will be warmed starting from the beginning of anesthesia.~The INDITHERM Medical Alpha, which is a resistive heater, will be applied to patients starting at the beginning of anesthesia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COVIDIEN WarmTouch
Description: COVIDIEN WarmTouch will be used as an active air blowing heater. Patients will be warmed starting from the beginning of anesthesia.~The INDITHERM Medical Alpha, which is a resistive heater, will be applied to patients starting at the beginning of anesthesia.
Study: NCT05588843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443122
Description: oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443122
Description: oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443122
Description: oral capsule
Study: NCT04967807

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac PET/MRI
Description: An imaging technique that combines the strengths of both MRI and PET into one comprehensive study. This technique allows for detailed myocardial tissue characterization with MRI (including assessment of myocardial edema and fibrosis) and metabolic changes (including myocardial inflammation).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac PET/MRI
Description: An imaging technique that combines the strengths of both MRI and PET into one comprehensive study. This technique allows for detailed myocardial tissue characterization with MRI (including assessment of myocardial edema and fibrosis) and metabolic changes (including myocardial inflammation).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood Biomarkers
Description: Markers of cardiac damage, inflammation, circulating microRNA profiles, and COVID antibody levels will be evaluated in patients after COVID-19 vaccination.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood Biomarkers
Description: Markers of cardiac damage, inflammation, circulating microRNA profiles, and COVID antibody levels will be evaluated in patients after COVID-19 vaccination.
Study: NCT04283812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS Electrode Implantation using D1 Sterotactic System
Description: Treatment intervention will consist of subjects undergoing Mayo Clinic standard deep brain stimulation surgery specific to their diagnosed neurological disorder consisting of implantation of stimulating electrodes using the D1 stereotactic system.
Study: NCT04917848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-Geriatric Oncology program
Description: Participants will be scheduled to meet with a Geriatric Nurse Practitioner (GNP) or Geriatric Registered Nurse (GRN) via the program's telemedicine platform. The telemedicine encounters with the GNP/GRN may occur every 2 weeks over 3 months, for a total of 6 visits. Visits 1 and 6 are mandatory, and visits 2-5 are on an as needed basis.
Study: NCT05588843

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule
Study: NCT05958823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block
Description: Serratus anterior plane block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PECS I-II
Description: PECS I-II
Study: NCT06113536

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasonographic evaluation
Description: Ultrasonographic evaluation for assessment of possible meniscal extrusion
Study: NCT05453695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous DNase I
Description: Dose-escalating intravenous infusion of DNase I
Study: NCT05611931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose: 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
Study: NCT05293860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connective tissue manipulation
Description: Connective tissue manipulation will be applied to participants' back for 5-20 minutes, 3 times a week for 4 weeks in this group.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Superficial massage with the head of the therapeutic ultrasound device
Description: Superficial massage with the head of the therapeutic ultrasound device will be applied to participants' back for 15 minutes, 3 times a week for 4 weeks in this group.
Study: NCT06014177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STIckER
Description: STIckER is an interactive and personalized intervention based on the principles of SDM that has been designed with input from the AYA ED patients and providers. STIckER guides AYA patients through a series of steps, beginning with scanning your STIckER. Participants complete risk assessments, SDM modules, and conclude with an anonymous final digital infographic that informs an SDM conversation with the medical provider. This decision aid seamlessly integrates into the ED workflow, recommending appropriate STI testing for high-risk individuals and using SDM concepts for those at intermediate risk.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: After enrollment but before the start of their clinical visit, AYA participants assigned to a provider in the control arm will scan a QR code. They will receive a prompt stating, If you would like to be tested for a sexually transmitted infection today, please tell your medical doctor.
Study: NCT04591106

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging (MRI)
Description: Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging (MRI)
Description: Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging (MRI)
Description: Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance elastography (MRE)
Description: Magnetic resonance elastography (MRE) is a non-invasive imaging technique that uses a gently vibrating transducer in combination with MRI to create detailed images and maps of the mechanical properties, such as stiffness, of tissues within the body.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance elastography (MRE)
Description: Magnetic resonance elastography (MRE) is a non-invasive imaging technique that uses a gently vibrating transducer in combination with MRI to create detailed images and maps of the mechanical properties, such as stiffness, of tissues within the body.

Intervention type: DEVICE
Intervention: Prototype MRE soft flexible passive transducer paddle
Description: The prototype device is provided to the investigators by Mayo Clinic under a Materials Transfer Agreement (MTA). The device is being used to promote comfort in the pediatric population; no formal data collection for regulatory submission is planned. The prototype device is smaller, softer, and more flexible than the commercial device and will be used where indicated by the subjects' size.

Intervention type: DEVICE
Intervention: Prototype MRE soft flexible passive transducer paddle
Description: The prototype device is provided to the investigators by Mayo Clinic under a Materials Transfer Agreement (MTA). The device is being used to promote comfort in the pediatric population; no formal data collection for regulatory submission is planned. The prototype device is smaller, softer, and more flexible than the commercial device and will be used where indicated by the subjects' size.
Study: NCT05030233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-Administered Touch Intervention
Description: The nurse-administered touch intervention is a bare-handed, comforting touch intervention administered during an episode of essential nursing care. The bedside nurse will cradle the infant's head with one hand, using the other hand to gently support the infant's lower body and legs in a flexed position. The touches will be administered for 1 minute at the start of the essential care episode, 30 seconds after the diaper change, and 1 minute at the conclusion of the care episode.
Study: NCT05128591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 18mg Oral Tablet
Description: AD-109 (Rivaroxaban 18mg) Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 18mg Oral Tablet
Description: AD-109 (Rivaroxaban 18mg) Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 MG Oral Tablet
Description: AD-1091 (Rivaroxaban 20mg) Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 MG Oral Tablet
Description: AD-1091 (Rivaroxaban 20mg) Oral Tablet
Study: NCT06152380

Intervention type: OTHER
Intervention: Knee Care @Home Programme
Description: Over 24 weeks after undergoing surgical reconstruction of the anterior cruciate ligament, patients in the intervention group will receive supervised guidance on therapeutic exercises to be performed at home. This guidance will be provided through individualised synchronous internet-based remote sessions using conferencing software.
Study: NCT05611931

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for selinexor
Description: Dose:60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
Study: NCT04797988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eon® FR 1064 nm device
Description: The subject will be treatment area - flanks, will be treated with the eon device.
Study: NCT05530486

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CC
Description: Application of placebo LASER

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LG1
Description: Application of LASER GasAs 660nm 4 J/cm².

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LG2
Description: Application of LASER GasAs 660nm 8 J/cm².

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LG3
Description: Application of LASER GasAs 660nm 12 J/cm².

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing
Description: Application of Helianthus annuus oil dressing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing
Description: Application of Helianthus annuus oil dressing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing
Description: Application of Helianthus annuus oil dressing.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dressing
Description: Application of Helianthus annuus oil dressing.
Study: NCT05628883

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBio-4101
Description: TBio-4101 is a tumor-infiltrating lymphocyte (TIL) product that involves the use of special immune cells called T-cells. A T-cell is a type of lymphocyte, or white blood cell.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL over approximately 1 hour per day for 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Participants will receive an intravenously (IV) infusion of Fludarabine 25 mg/m2 for approximately 15 to 30 minutes for 5 days, prior to T-Cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Participants will receive Interleukin-2 (IL-2) 600 000 IU/kg intravenously every 8 to 12 hours beginning within 24 hours after T-cell infusion.